Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

BACKGROUND: We analysed whether the level of human epidermal growth factor receptor-2 (HER-2) amplification significantly influenced either pathological complete response (pCR) or recurrence-free survival (RFS) and overall survival (OS) after trastuzumab-based neoadjuvant therapy. METHODS: In all, 9...

Descripción completa

Detalles Bibliográficos
Autores principales: Guiu, S, Gauthier, M, Coudert, B, Bonnetain, F, Favier, L, Ladoire, S, Tixier, H, Guiu, B, Penault-Llorca, F, Ettore, F, Fumoleau, P, Arnould, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990615/
https://www.ncbi.nlm.nih.gov/pubmed/20978512
http://dx.doi.org/10.1038/sj.bjc.6605939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990615/
https://www.ncbi.nlm.nih.gov/pubmed/20978512
http://dx.doi.org/10.1038/sj.bjc.6605939

Ejemplares similares